SAN FRANCISCO, May 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics …
BioMarin – Update for Achondroplasia Associations
As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the …
QED COVID-19 Update
Dear Chandler Project, We at QED know that this is a challenging time for all families. We hope that you are all …
Study of Infigratinib in Children With Achondroplasia
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, …
QED Achondroplasia Clinical Update
QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (“BridgeBio”) focuses on bringing medicine to …
BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301)
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated …